<DOC>
	<DOCNO>NCT02545543</DOCNO>
	<brief_summary>This study ass immune ( antibody ) response safety Seqirus split virion , inactivated Quadrivalent Influenza Vaccine ( Seqirus QIV ) , comparison US license 2015/2016 Quadrivalent Influenza Vaccine ( comparator QIV ) healthy pediatric population 5 17 year age .</brief_summary>
	<brief_title>A Study Evaluate Immunogenicity Safety Seqirus Quadrivalent Influenza Vaccine ( QIV ) Pediatric Population 5 Through 17 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males females 5 17 year age day first study vaccination . Parent legally acceptable representative able provide write informed consent willing able adhere protocol requirement include blood draw . Participant assent also obtain require . If applicable , female childbearing potential ( ie , ovulate , surgically sterile ) must abstinent willing use medically accept contraceptive regimen least 28 day last Study Vaccine . Females childbearing potential must return negative urine pregnancy test result , prior vaccination dose Study Vaccine . History allergic reaction egg proteins component Study Vaccines . History serious adverse reaction influenza vaccine . History GuillainBarré syndrome demyelinate disease . History license investigational influenza vaccination last 6 month . Clinical sign active infection and/or oral temperature ≥ 100°F ( 37.8°C ) day plan Study Vaccine administration within 48 hour precede vaccination . Current recent , acute chronic medical condition opinion Investigator clinically significant and/or unstable ( illness exacerbation ) within precede 30 day . History seizure , exception single febrile seizure . Selfreported known seropositivity suggestive acute chronic viral infection human immunodeficiency virus , hepatitis B hepatitis C. Known suspect congenital acquire immunosuppressive condition . Current recent immunosuppressive immunomodulatory therapy , follow : Chronic longterm systemic corticosteroid : ≥ 0.125 mg/kg/day oral prednisolone equivalent daily ; Sporadic systemic corticosteroid : ≥ 0.5 mg/kg/day oral prednisolone equivalent two short course &gt; 3 day 3 month precede vaccination ; Antineoplastic chemotherapy radiation therapy within 6 month precede vaccination . Note : Use topical , inhalant localise tissue injection corticosteroids prior administration Study Vaccine throughout study acceptable . Administration immunoglobulin and/or blood product within 3 month precede vaccination , plan administration study . Participation clinical trial use investigational compound within 28 day prior first dose Study Vaccine , within 28 day receive final indicate dose Study Vaccine , plan enter study period . Vaccination license vaccine 28 day ( live inactivate vaccine ) prior receive first dose Study Vaccine , plan receive license vaccine prior Study Exit Visit . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>